Induction and the epitope analysis of human T cells specitic for human papilloma virus

人乳头瘤病毒特异性T细胞的诱导和表位分析

基本信息

  • 批准号:
    10670434
  • 负责人:
  • 金额:
    $ 2.05万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1998
  • 资助国家:
    日本
  • 起止时间:
    1998 至 2000
  • 项目状态:
    已结题

项目摘要

In order to investigate immune surveilence system for malignant tumors, it is important to know cellular immunity specific for tumor cells. Human papillomaviruses (HPVs) an useful tool to study cellular immune response agaist viruses and cancers induced by the viruses during the chronic infection, bscause papillomaviruses is almost established to be the cause of human cervical cancers among about 70% of the patients.We tested the cytolytic T cell (CTL) response against the truncated peptides of HPV16 E6 and E7 oncogenes from peripheral blood cells of the infected subjects detected by RT-PCR analysis of cervical cells. We could detect the CTL rsponse in 5 subjects among 150 subjects in HPV16- infected subjects. We also try to detect the minimum T cell epitopes of these CTL, and determine the HLA restriction and cell surface marker of these cells. We also induced the helper T cells specific for HPV16 E6 and E7 peptides using IL-2 response as the marker, and also detected several helper T cells specific for these petides. We try to induce the specific helper and killer clones in these cells, to know the mechanisms of T cell recognition agaist the oncogene products. We would like to study the minimum epitopes of these cells and HLA restriction to investigate the pathogenesis of cervical cancer, and the possibility of peptide vaccine for cervical neoplasms.
为了研究恶性肿瘤的免疫监测系统,了解肿瘤细胞特异性的细胞免疫至关重要。人乳头瘤病毒(hpv)是研究慢性感染过程中细胞对病毒的免疫反应和病毒引起的癌症的有用工具,因为乳头瘤病毒几乎被确定是人类宫颈癌的病因,约占70%的患者。采用RT-PCR方法检测宫颈细胞中hpv16e6和E7癌基因截短肽对感染者外周血细胞的细胞溶解T细胞(CTL)反应。我们在150例HPV16感染者中检测到5例CTL反应。我们还尝试检测这些CTL的最小T细胞表位,并确定这些细胞的HLA限制性和细胞表面标记。我们还利用IL-2反应作为标记,诱导了HPV16 E6和E7肽特异性的辅助T细胞,并检测了这些肽特异性的几种辅助T细胞。我们试图在这些细胞中诱导特异性的辅助克隆和杀伤克隆,以了解T细胞识别癌基因产物的机制。我们希望通过研究这些细胞的最小表位和HLA限制来探讨宫颈癌的发病机制,以及宫颈癌肽疫苗的可能性。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tsukui T: "Aging increases, and duodenal ulcer reduces the risk for intestinal metaplasia of the gastric corpus in Japanese patients with dyspepsia"J.of Gastroenterol and Hepatol. 16. 15-21 (2001)
Tsukui T:“老龄化加剧,十二指肠溃疡降低了日本消化不良患者胃体肠化生的风险”J.of Gastroenterol and Hepatol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tsukui T: "Aging increases, and duodenal ulcer reduces the risk for intestinal metaplasia of the gastric corpus in Japanese patients with dyspepsia."J.Gastroenterol and Hepatol.. 16. 15-21 (2001)
Tsukui T:“老龄化增加,十二指肠溃疡降低了日本消化不良患者胃体肠化生的风险。”J.Gastroenterol and Hepatol.. 16. 15-21 (2001)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tsukui T, Kashiwagi R, Sakano M et al.: "Aging intreases, and duodenal Llcer reduces the risk for intestinal motaplasia of the gastric corpus in Japanese patients with dyspepsia."J Gastroenterol Hepatol. Jan(16). 15-21 (2001)
Tsukui T、Kashiwagi R、Sakano M 等人:“衰老和十二指肠溃疡可降低日本消化不良患者胃体肠异生的风险。”J Gastroenterol Hepatol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TSUKUI Taku其他文献

TSUKUI Taku的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Optimizing HPV vaccination programs in Low- and Middle-Income Countries (LMIC) and High-Income Countries (HIC) to reduce inequalities and reach global elimination of cervical cancer: An integrated knowledge translation dynamic-modeling approach
优化中低收入国家 (LMIC) 和高收入国家 (HIC) 的 HPV 疫苗接种计划,以减少不平等并实现全球消除宫颈癌:综合知识转化动态建模方法
  • 批准号:
    495110
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Operating Grants
The Social Impact of Cervical Cancer on Women and their Children in Uganda
宫颈癌对乌干达妇女及其儿童的社会影响
  • 批准号:
    495276
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Experiences of early-stage cervical cancer and fertility sparing surgery: an ethnographic and co-creative approach to social and intimate domains
早期宫颈癌和保留生育手术的经验:社会和亲密领域的民族志和共同创造方法
  • 批准号:
    EP/Y023617/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Fellowship
Development of an HPV stigma assessment scale and a stigma-reducing intervention to improve cervical cancer prevention in El Salvador
制定 HPV 耻辱评估量表和减少耻辱干预措施,以改善萨尔瓦多的宫颈癌预防
  • 批准号:
    10844859
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
接受免疫治疗和放化疗的局部晚期宫颈癌患者结果的免疫基因组预测因子
  • 批准号:
    10908093
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
KEMRI-PHRD UG1 CASCADE NETWORK UNIT: CERVICAL CANCER PREVENTION FOR WOMEN LIVING WITH HIV RESEARCH
KEMRI-PHRD UG1 级联网络单元:艾滋病毒感染女性的宫颈癌预防研究
  • 批准号:
    10763054
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Point of Care HPV 16/18/45 DNA Test for Cervical Cancer
宫颈癌护理点 HPV 16/18/45 DNA 检测
  • 批准号:
    10896570
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Zimbabwe (ZIM-CASCADE)
在津巴布韦实施艾滋病毒/宫颈癌预防 CASCADE 临床试验 (ZIM-CASCADE)
  • 批准号:
    10758129
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
The Economic Impact of Cervical Cancer on Women and Children in Uganda
宫颈癌对乌干达妇女和儿童的经济影响
  • 批准号:
    492688
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Targeting LOX-1 for MDSC-inhibition therapy against cervical cancer
以 LOX-1 为靶点进行 MDSC 抑制治疗宫颈癌
  • 批准号:
    23K06666
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了